Skip to Content

Phase II study of marqibo in patients with metastatic uveal melanoma

Objective
This is a clinical trial of marqibo that will be given through intravenous (I.V.) infusion. Marqibo is investigational.
IRB Protocol Number
08-0522
Principal Investigator(s)
RENE GONZALEZ

Cancer Trials

  • Melanoma (Except Eye)
Sponsor(s)
HANA biosciences
Contact
MICHAEL CROSS at 720-848-0592
or MICHAEL.CROSS@UCDENVER.EDU
Eligibility and Other Participant Information
What To Expect : A screening period to determine eligibility. A treatment period that can last as long as you are benefitting from the investigational drug. A follow up period will consist of a phone call once every 3 months. // Eligibility criteria include but are not limited to 18 years or older with metastatic uveal (ocular) melanoma.